Curis (NASDAQ:CRIS) Upgraded at Wall Street Zen

Curis (NASDAQ:CRIS) was upgraded by Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Several other research analysts have also issued reports on CRIS. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Curis in a research note on Friday, March 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.00.

Curis Price Performance

Shares of Curis stock opened at $0.56 on Friday. The firm has a market capitalization of $7.63 million, a PE ratio of -0.47 and a beta of 3.02. The company’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.21. Curis has a 52-week low of $0.52 and a 52-week high of $3.13.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $3.25 million. Analysts predict that Curis will post -7.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CRIS. Squarepoint Ops LLC boosted its holdings in shares of Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 8,973 shares in the last quarter. Jane Street Group LLC increased its holdings in Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. Focused Wealth Management Inc raised its position in Curis by 33.8% in the 3rd quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 19,995 shares during the last quarter. XTX Topco Ltd bought a new position in Curis in the 4th quarter valued at $26,000. Finally, Warberg Asset Management LLC acquired a new position in Curis in the third quarter worth $73,000. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.